Why the Abcam price fall was a reminder of the risks of high flying stocks

Thursday, Sep 13 2018 by
45
Why the Abcam price fall was a reminder of the risks of high flying stocks

Shares in the life-sciences company Abcam fell by 15 percent when it published its full year results this week. At one point during the day, its price was down by more than 30 percent.

For random observers (who may not have even heard of Abcam), the cause of this savage drop might have looked obvious - the antibody specialist must have undershot expectations. But that wasn’t the case at all. Abcam’s results were in line with forecasts. Revenues were up, targets were hit and even the dividend was hiked by 18 percent. So why did the price tumble so sharply?

5b9a24578abc1A2.png

The answer was that Abcam said it was planning to invest more in research, development and expansion. Inevitably that would put pressure on earnings in the coming years, and it was this that rattled the market. Pressure on earnings is not something that Abcam shareholders are used to.

Good news… bad reaction

It’s quite common for investors to be left bemused when share prices fall on what seems like decent financial results. The causes vary, but Abcam is an interesting case. With a market cap now of £2.7 billion, it’s one of the largest companies quoted on the Alternative Investment Market (AIM). It’s also one of the most profitable. In fact, Abcam has a solid track record of growing profitability, cash generation and efficiency. This has made it very attractive to many investors. But its popularity meant it was particularly vulnerable to a stomach-churning price drop, and here’s why…

Abcam belonged - and still belongs - to a group of stocks with an investment profile we call High Flyers. They have some eye-catching quality characteristics, meaning they’re profitable, often resistant to competition and financially robust. A reputation for quality earns them support in the market. Consistent overachievement in earnings growth makes them popular. And that manifests itself in relentless price momentum.

So stocks like Abcam are appealing for their good quality and strong momentum. But the flipside of the coin is that they can end up looking expensive against regular valuation metrics. But some investors believe that eye-watering prices can be justified if earnings in a company are growing rapidly.

It was that kind of momentum that propelled Abcam’s shares from £5 to £15 in a little over three years. In that time, its average price-earning…

Unlock this article instantly by logging into your account

Don’t have an account? Register for free and we’ll get out your way

Disclaimer:  

As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested. ?>


Do you like this Post?
Yes
No
45 thumbs up
0 thumbs down
Share this post with friends



Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company's purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways. The Company is engaged in data sharing and ecommerce in the life sciences. The Company focuses on helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use its affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences. It has approximately 10 locations located in the world, through life science research hubs, enabling local services and multi-language support. more »

LSE Price
1384p
Change
-0.8%
Mkt Cap (£m)
2,861
P/E (fwd)
40.8
Yield (fwd)
1.0



  Is LON:ABC fundamentally strong or weak? Find out More »


10 Comments on this Article show/hide all

andrea34l 13th Sep 1 of 10
1

Domino's Pizza (LON:DOM) is actually another victim of growth faltering, after the CFO departed and then somewhat lacklustre results recently. The high was around 385, it's now at 281

| Link | Share | 1 reply
herbie47 13th Sep 2 of 10
2

I thought Abcam (LON:ABC) were below forecast? Yes but the price soon recovered, I thought the fall was overdone, if I had seen them at around 1020p I would have bought shares, another similar case has been Frontier Developments (LON:FDEV) that fell about 30% on results that were ahead of forecasts again they soon recovered. So I'm seeing buying opportunities here. The time to sell these type of shares is when growth begins to slow, that's why I sold Domino's Pizza (LON:DOM). But the High Flyers and CAMSLIM screens have done very well, many people sell out too early, myself included, I did that with Boohoo (LON:BOO) and £FVER.

| Link | Share
bluecurve 13th Sep 3 of 10
2

Another High Flyer, Blue Prism (LON:PRSM), down around 8% this morning - at one point down 25%. No news that I'm aware of, just a piece on FT Alphaville that points out the obvious (it's loss making and has competition). I hold a small position in this and the share price has done very well over the last 18 months (+350%)

I'm well aware that, although a High Flyer, the underlying financials don't support the valuation - it's more of a story stock. Whether profitable or not, It's surprising how quickly sentiment can change on very little news, and what few buyers there can be to support these types of stocks when someone decides to sell in size.

| Link | Share
JohnEustace 13th Sep 4 of 10
1

In reply to post #398454

I see that Keith Ashworth-Lord has sold out of Domino's Pizza (LON:DOM) in his Buffetology fund. His latest newsletter highlights the fact that the CEO has gone through three FD's in less than five years and is at loggerheads with a number of franchisees.

| Link | Share
Roger Lawson 13th Sep 5 of 10
3

As Abcam is one of my bigger holdings, the abrupt share price fall was certainly a shock - see my blog post on the subject here: https://roliscon.blog/2018/09/11/brexit-abcam-victoria-and-the-beaufort-case/ . To some extent, after a positive recent run I think the share price got a bit ahead of where it should have been, but it's worth noting that the directors were buying today.

Website: Roliscon
| Link | Share | 1 reply
ACounsell Fri 6:09pm 6 of 10
5

Not a holder of Abcam (LON:ABC) but do feel this is a classic example of the short termism prevalent in much of the investment fraternity - notably City institutions. The reason for the fall despite 'in-line' results according to Ben's article 'was that Abcam (LON:ABC) said it was planning to invest more in research, development and expansion' and this would 'put pressure on earnings in future years'. This is not the first company to make this type of a statement with a resultant hit to a high flying share price but I would ask how can a technology business grow revenue and earnings in the longer term? By 'investing more in research, development and expansion' I would suggest! At least that is what the likes of £AAPL have done and they are now a trillion dollar company so it would seem to pay off 'long term' for the company and the shareholders.

| Link | Share
twiggytwo Wed 9:15am 7 of 10
1

Very interesting article as Abcam has been one of my best performing stocks over the last 3 years and it was a nasty shock to see the price fall after such good results. I bought this as a 'fledgling' and on Jim Slater fundamentals which seem to work well along with plenty of research about the company. It appeared to have products which were original and not easily copied and I think that still holds so will stick with it!

| Link | Share
FREng Wed 9:32am 8 of 10
1

In reply to post #398574

Roger

Were the directors actually making a discretionary purchase of the shares, or was it an automatic purchase as a result of their remuneration agreements? The announcements make it seem the latter.

| Link | Share
bill772037 Wed 4:50pm 9 of 10

as a holder of Abcam I was disappointed but I am in favour of more expenditure on R&D . Bodes well for the future

| Link | Share
shine66 Wed 11:01pm 10 of 10
1

'At one point during the day, its price was down by more than 30 percent.'

Presumably by then most holders would have had their stop loss hit?


| Link | Share

What's your view on this article? Log In to Comment Now

You can track all @StockoChat comments via Twitter

 Are LON:ABC's fundamentals sound as an investment? Find out More »





Stock Picking Tutorial Centre



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis